- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 16 Aug 23 424B5 Prospectus supplement for primary offering
- 14 Aug 23 424B5 Prospectus supplement for primary offering
- 27 Jun 23 424B5 Prospectus supplement for primary offering
- 23 Jun 23 424B5 Prospectus supplement for primary offering
- 18 Nov 22 424B5 Prospectus supplement for primary offering
- 17 Nov 22 424B5 Prospectus supplement for primary offering
- 10 Jun 22 424B5 Prospectus supplement for primary offering
- 29 Mar 21 424B5 Prospectus supplement for primary offering
- 26 Mar 21 424B5 Prospectus supplement for primary offering
- 8 Dec 20 424B5 Prospectus supplement for primary offering
- 4 Dec 20 424B5 Prospectus supplement for primary offering
- 24 Nov 20 EFFECT Notice of effectiveness
- 19 Nov 20 S-3/A Shelf registration (amended)
-
5 Nov 20 S-3 Shelf registration
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement of TFF Pharmaceuticals, Inc. on Form S-3 of our report dated March 26, 2020, with respect to our audits of the consolidated financial statements of TFF Pharmaceuticals, Inc. as of December 31, 2019 and 2018 and for the year ended December 31, 2019, period from January 24, 2018 to December 31, 2018 and period from January 1, 2018 to January 23, 2018 (Predecessor), appearing in the Annual Report on Form 10-K of TFF Pharmaceuticals, Inc. for the year ended December 31, 2019. We also consent to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ Marcum llp
Marcum llp
New York, NY
November 5, 2020